|
MVA and DNA Based SARS-CoV-2 Vaccines
Application
Modified Vaccinia virus Ankara (MVA)- and deoxyribonucleic acid (DNA)-based vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Key Benefits
Safety profile is known.
Demonstrated antiviral activity against related Coronaviruses.
Single dose of vaccination was shown to be effective against related Coronaviruses...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Sailaja Gangadhara
|
|
Combination Antibiotic Therapy to Exploit Multiple Heteroresistance
Application
Treatment with combinations of FDA-approved antibodies targeting small drug-resistant cell populations for infectious disease.
Key Benefits
Specific combinations of existing drugs that target small subpopulations of bacterial cells resistant to many standard of care treatment regimens.
Potential to overcome the drug resistance crisis...
Published: 2/13/2025
Contributor(s): David Weiss, David Hufnagel, Victor Band
|
|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 2/13/2025
Contributor(s): Joanna Goldberg, Dina Moustafa
|
|
Generation of Vaccines Preventing the Common Cold
Application
A new class of vaccines targeting the viruses causing the common cold, rhinoviruses (RV).
Key Benefits
Capsid-chimeric strains for developing new RV vaccines.
Preclinical data with a prototype show the ability to induce a robust capsid-specific immune response.
Straightforward and inexpensive vaccine manufacturing process utilizing...
Published: 2/13/2025
Contributor(s): Sujin Lee
|
|
Reagents and Hardware for RNA Storage at Ambient Temperatures
Application
Simple and economical method for isolating and storing RNA from biological samples at room temperatures.
Key Benefits
Alternative, low-cost extraction method suitable for extracting RNA from biological samples for molecular analysis and disease diagnosis.
Eliminates the need for expensive proprietary materials, hazardous chemicals,...
Published: 2/13/2025
Contributor(s): Jesse Waggoner, David Myers, Sarah Hernandez, Dhruv Miglani
|
|
RSV Vaccine for Infants and Children
Application
Vaccine for Respiratory Syncytial Virus (RSV) in infants and children.
Key Benefits
A novel vaccine targeting both the F and G proteins of the respiratory syncytial virus (RSV), including its variants.
Preliminary data in in mice show the vaccine induced the production of antibodies associated with preventing disease.
Potential to...
Published: 2/13/2025
Contributor(s): Larry Anderson, Binh Ha, Heying Sun
|
|
Therapeutic for Potential Elimination of Chronic Hepatitis B
Application
A therapeutic technique to eliminate infection of patients suffering from chronic Hepatitis B Virus infection.
Key Benefits
May provide a cure for chronic HBV infection rather than just simple management.
High efficiency of infection targeting may produce minimal side effects.
May be used in combination with other HBV inhibitors.
Market...
Published: 2/13/2025
Contributor(s): Raymond Schinazi, Leda Bassit, Ting Nie
|
|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 2/13/2025
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
Isolation of Therapeutic cells and Framework for Adoptive Cell Therapies
Application
Isolation of therapeutic cells and framework for adoptive cell therapies based around stem-like chronic memory CD8 T cells that may be paired with PD-1 blockade.
Key Benefits
Persistent cell survival and therapeutic efficacy following rechallenge with chronic viral infection and cancer.
Strong co-treatment potential with PD-1...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Daniel Chang
|
